Pharming Group N.V.
Research Pharming Group N.V. (PHAR) on Bullrun: valuation model: 36.5% overvalued, market cap USD 939.88M, P/E 77.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPHAR
- ExchangeNASDAQ
- CountryNetherlands
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal36.5% overvalued
- Market capUSD 939.88M
- P/E77.8
- Financial periodQ1 2026
- RevenueUSD 369.49M
- Net income-USD 5.21M
- Free cash flowUSD 1.71M
- Gross margin17.8%
Valuation Snapshot
Bullrun's latest valuation model marks Pharming Group N.V. as 36.5% overvalued; latest market cap is USD 939.88M; P/E is 77.8.
About Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE);
Frequently asked questions
Is Pharming Group N.V. overvalued or undervalued?
Bullrun's valuation model currently marks Pharming Group N.V. as 36.5% overvalued.
What is Pharming Group N.V.'s market cap?
Pharming Group N.V.'s market capitalization is USD 939.88M.
What is Pharming Group N.V.'s P/E ratio?
Pharming Group N.V.'s price-to-earnings (P/E) ratio is 77.8.
What does Pharming Group N.V. do?
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.